Johnson & Johnson’s Kenvue consumer health business has been valued at around US$41bn in its initial public offering.
The company announced it will list 172,812,560 shares at a price of $22 per share, slightly above the middle of its price range.
Read more:
Johnson & Johnson readies IPO for Kenvue consumer health business
It had earlier announced its intention to sell shares at a range between $20 and $23 per share.
The stock will begin trading on the New York Stock Exchange under the symbol KVUE today.
J&J will continue to own more than 90% of Kenvue’s shares.
The deal is said to be the largest IPO pan-industry to launch since electric vehicle maker Rivian Automotive listed its shares on Nasdaq in late 2021.